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PENCIRIAN HOMOLOG BAGI GEN BRUGIA MALAYI (Bm17DIII) YANG 
SIGNIFIKAN SECARA DIAGNOSTIK DI DALAM WUCHERERIA BANCROFTI, LOA 
LOA  
DAN ONCHOCERCA VOLVULUS 
 
 
ABSTRAK 
 
 
Satu ujian pantas yang dikenali sebagai BRUGIArapid (BR) yang mengesan antibodi 
IgG4 terhadap antigen rekombinan B. malayi (BmR1) adalah sangat berguna dalam 
pemetaan dan pengawasan kawasan yang endemik bagi filariasis brugia. Kajian 
penilaian lapangan yang telah dilakukan menunjukkan bahawa BmR1 adalah sangat 
sensitif dan spesifik dalam mengesan individu bermikrofilaria. Corak reaktiviti IgG4 
terhadap BmR1  daripada sampel individu yang terjangkit dengan W. bancrofti adalah 
berbeza-beza mengikut kawasan, manakala reaktiviti BmR1 terhadap sampel serum 
daripada individu yang dijangkiti O. volvulus dan L. loa adalah sangat minima.  
 
Memandangkan antigen rekombinan BmR1 adalah  signifikan secara diagnostik, maka 
adalah penting untuk mencirikan BmR1 secara lebih mendalam. Perbezaan reaktiviti 
BmR1 terhadap sampel serum daripada pesakit yang dijangkiti parasit filarial yang lain 
(selain B. malayi & B. timori) mencetuskan persoalan samada antigen tersebut 
mempunyai gen homolog di dalam W. bancrofti (Wb-BmR1), O. volvulus (Ov-BmR1) 
dan L. loa (Ll-BmR1). Sehubungan dengan itu, dalam kajian ini, jujukan DNA dan/atau 
cDNA bagi W. bancrofti, O. volvulus dan L. loa dikenalpasti, proteinnya diekspresi dan 
reaktiviti terhadap sampel serum  pesakit diuji.  
 
Pencarian homolog berasaskan web bagi Bm17DIII di dalam W. bancrofti, O. volvulus 
dan L. loa menggunakan beberapa pangkalan data DNA melalui server BLASTN 
menunjukkan tiada sebarang persamaan dengan jujukan W. bancrofti dan L. loa, 
manakala bagi O. volvulus, terdapat persamaan dengan dua jujukan L3 dengan nilai 
E-value yang rendah. Pencarian homolog melalui BLASTP (pangkalan data protein) 
menunjukkan protein BmR1 tidak mempunyai persamaan dengan jujukan protein lain. 
 
Kaedah PCR digunakan untuk pemencilan dan identifikasi jujukan cDNA daripada 
perpustakaan cDNA dan/atau DNA genomik daripada W. bancrofti, O. volvulus dan L. 
loa menggunakan primer RNR dan RNF. Produk PCR bersaiz 618 bp (iaitu Wb-BmR1, 
Ov-BmR1 dan Ll-BmR1) kemudiannya diklon ke dalam vector TOPO, dijujuk dan 
dianalisis menggunakan program Vector NTI dan server BLAST. Wb17DIII didapati 
100% menyerupai jujukan BmR1, manakala Ov17DIII dan Ll17DIII didapati mirip 
terhadap satu sama lain dan berkongsi homologi sebanyak 99.7% dengan Bm17DIII. 
Oleh itu keputusan pencarian gen homolog Ov17DIII melalui web tidak selaras dengan 
keputusan yang diperolehi dalam makmal. Kajian ini juga menunjukkan bahawa 
keseluruhan gen Wb17DIII tidak mengandungi sebarang intron; dengan itu berbeza 
daripada gen Bm17DIII yang mempunyai satu intron dan dua ekson. 
 
Gen rekombinan Ov17DIII or Ll17DIII kemudiannya diekspresi di dalam pPROEXTM 
HTa/TOP10F. Molekul Ov-BmR1 or Ll-BmR1 didapati bersaiz ~25 kDa dan analisis 
secara blot Western menunjukkan ia reaktif terhadap sampel serum daripada pesakit 
L. loa dan O. volvulus yang bermikrofilaria dan tidak reaktif dengan sampel serum 
daripada penderma darah yang sihat. Dengan menggunakan kaedah IgG4-ELISA, 
corak pengenalan antibodi IgG4 dalam semua sampel serum didapati sama terhadap 
BmR1 dan Ov-BmR1 or Ll-BmR1. ini termasuklah reaktiviti antibodi IgG4 yang lemah 
yang dipamerkan oleh  sampel serum daripada pesakit yang dijangkiti O. volvulus dan 
L. loa.  Kajian tentang reaktiviti terhadap subkelas IgG yang lain menunjukkan bahawa 
sampel serum daripada pesakit yang dijangkiti O. volvulus dan L. loa memberikan 
keputusan positif (bila diuji dengan Ov-BmR1 or Ll-BmR1 atau BmR1) hanya dengan 
IgG1 dan tidak dengan subkelas IgG2 atau IgG3. Begitu juga reaktiviti BmR1 terhadap 
sampel serum daripada individu yang terjangkit dengan B. malayi dan W. bancrofti 
(jangkitan aktif dan kronik) turut memberi reaktiviti positif terhadap IgG1 dan negatif 
terhadap subkelas antibodi IgG2 atau IgG3. Namun begitu, sampel serum daripada 
individu normal dan yang dijangkiti cacing bawaan tanah juga menunjukkan corak 
reaktiviti yang serupa (iaitu positif dengan IgG1 dan negatif dengan IgG2 & IgG3). 
 
Kajian ini menunjukkan bahawa homolog bagi antigen rekombinan BmR1 wujud di 
dalam W. bancrofti, O. volvulus dan L. loa dengan konservasi yang tinggi. 
Pengecaman antigen (BmR1, Wb-BmR1, dan Ov-BmR1 or Ll-BmR1) oleh sampel 
serum pesakit  adalah sama terhadap IgG1, IgG2 atau IgG3, tetapi berbeza bagi 
antibodi IgG4. Kesimpulannya ialah, walaupun antigen BmR1 adalah sesuai digunakan 
untuk pengesanan antibodi IgG4 terhadap jangkitan filariasis brugia, bagaimanapun, 
protein homolognya (Wb-BmR1, Ov-BmR1 dan Ll-BmR1) tidak sesuai digunakan bagi 
tujuan pengesanan jangkitan penyakit filaria yang lain. 
 
 
 
CHARACTERIZATION OF THE HOMOLOGS OF A DIAGNOSTICALLY 
SIGNIFICANT BRUGIA MALAYI GENE (Bm17DIII) IN WUCHERERIA BANCROFTI, 
LOA LOA  
AND ONCHOCERCA VOLVULUS 
 
 
 
ABSTRACT 
 
 
 
An antibody-detection rapid test, BRUGIArapid, that detects IgG4 antibodies reactive to 
a recombinant B. malayi antigen (BmR1), is a promising tool for mapping and 
monitoring the areas where brugian filariasis is endemic. Field trials have revealed that 
BmR1 is highly sensitive and specific in detecting microfilariaemic individuals. In sera 
of individuals infected with Wuchereria bancrofti the IgG4 reactivity to BmR1 is 
variable, and cross-reactivity of sera from individuals infected with O. volvulus or L. loa 
was observed only in single cases.  
 
Due to its diagnostic significance, it is therefore important to characterize the BmR1 
antigen more closely. The varying degree of BmR1 recognition in other filarial 
infections (other than B. malayi & B. timori) raises the question whether the 
homologous antigen is also present in W. bancrofti (Wb-BmR1), O. volvulus (Ov-
BmR1) and L. loa (Ll-BmR1).  In this study, the respective cDNA sequences were 
identified, the protein expressed and the antibody reactivities of patients’ sera to the 
homologous recombinant antigens was studied.   
 
Web-based homology searches for homologs of Bm17DIII in W. bancrofti, O. volvulus 
and L. loa via BLASTN server of several DNA databases resulted in no similarity to 
any sequence of W. bancrofti and L. loa, while for O. volvulus, there were two L3 
sequences which had a low E-value. Homology searches via BLASTP (protein 
databases) revealed that BmR1 protein did not have any similarity with other protein 
sequence.  
 
PCR was used to isolate the cDNA sequences from cDNA libraries and/or genomic 
DNA of W. bancrofti, O. volvulus and L. loa based on RNR & RNF primers. The 618 bp 
PCR products (namely Wb17DIII, Ov17DIII and Ll17DIII) was then cloned into TOPO 
vector, sequenced and analysed using Vector NTI software and BLAST server. 
Wb17DIII was found to be 100% identical to Bm17DIII, while Ov17DIII and Ll17DIII 
were found to be identical to each other and shared 99.7% homology with Bm17DIII. 
Thus the results of the web-based search for Ov17DIII were not in agreement with the 
laboratory results. This study also revealed that, unlike the complete Bm17DIII gene 
which contains an intron (and two exons), the complete Wb17DIII gene did not 
possess any intron.  
 
The Ov17DIII or Ll17DIII recombinant gene was then expressed in pPROEXTM 
HTa/TOP10F. The MW of Ov-BmR1 or Ll-BmR1 was ~25 kDa and analysis by 
Western blot showed reactivity with sera from L. loa and O. volvolus mf+ patients and 
no reactivity with serum from healthy blood donor. By employing IgG4-ELISA, the 
pattern of IgG4 recognition of all serum samples to Ov-BmR1 or Ll-BmR1 and BmR1 
was found to be identical. This included weak IgG4 reactivities demonstrated by sera 
from L. loa- and O. volvulus-infected patients. With respect to reactivities to other IgG 
subclasses, sera from O. volvulus- and L. loa- infected patients showed positive 
reactions (when tested with Ov-BmR1 or Ll-BmR1 or BmR1) only with IgG1; and  no 
reactivity was observed with IgG2 or with IgG3. Similarly, sera from individuals infected 
with B. malayi or W. bancrofti (active and chronically-infected patients) were positive 
with BmR1 only for IgG1 and were negative when tested with IgG2 and IgG3 
subclasses. However, it is also noted that sera from non-endemic normals and soil-
transmitted helminth infections also showed similar reactivities i.e. IgG1 positive and 
IgG2 and IgG3 negative.  
 
This study demonstrated that Bm17DII gene and its homologs in W. bancrofti, O. 
volvulus and L. loa are highly conserved. Recognition of the recombinant gene 
products (BmR1 or Wb-BmR1 and Ov-BmR1 or Ll-BmR1) by patients’ sera are similar 
with regard to IgG1, IgG2 and IgG3, but different for IgG4 antibodies. Thus this study 
demonstrated that although IgG4 antibodies to BmR1 are a good infection marker for 
brugian filariasis, its homologs are not of diagnostic value. 
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CHAPTER ONE 
 
 
 INTRODUCTION 
 
 
 
1.1 Human Filariasis 
Filariasis is caused by roundworms that inhabit the lymphatic and subcutaneous 
tissues and cause some of the most debilitating diseases, including elephantiasis and 
river blindness (WHO, 2002a,b; 2003). Human filarial infections are endemic in tropical 
regions (Figure 1.1) and affect an estimated 200 million people, and exposing another 
billion to the risk of infection (Ottesen et al., 1997). The parasites are transmitted by 
blood-feeding insects, which act as vectors. Filarial nematodes enter the human body 
at their third larval stage by escaping from the mouthparts of their vector arthropod as 
they bend during biting and enter through the bite wound in the skin.  
 
Eight main species infect human namely Wuchereria bancrofti, Brugia malayi and 
Brugia timori which causes lymphatic filariasis; Loa loa which causes loaisis; 
Onchocerca volvulus which causes onchocerciasis; and three species of Mansonella.  
 
Filariasis is rarely fatal, it is the second leading cause of permanent and long-term 
disability in the world. The World Health Organization (WHO) has named filariasis one 
of only six “potentially eradicable” infectious diseases and has embarked upon a 20-
year campaign to eradicate the disease. The immunologic hallmark of infections by 
filarial parasites is induction of allergic type responses (Bundy et al., 1991, King, 2000). 
Typically this produces peripheral eosinophilia and elevated levels of polyclonal and 
parasite specific IgE. Filarial specific IgG subclasses are also present, with IgG4 
subclass most prominently elevated (Ottesen et al., 1985). 
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Figure 1.1 A map showing filariasis endemic countries (WHO, 1997).  
  
 
 
 
 
 
 
 
 
1.2 Lymphatic Filariasis 
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Lymphatic filariasis (LF) also known as elephantiasis is a disabling and disfiguring 
infection caused by W. bancrofti, B. malayi or B. timori (Michael and Bundy, 1997). It is 
estimated that 120 million people or 2% of the world’s population are infected in around 
80 countries throughout the tropics and subtropics (WHO, 2000; WHO, 2002; 
Molyneux, 2003).  
 
It is a major cause of acute and chronic morbidity affecting persons of all ages and 
both sexes (Ottesen, et al., 1997) and prevails in those of low socioeconomic level 
(Dreyer, et al., 2000). LF is a major burden on health and hospital resources 
(Gyapong, et al., 1996) includes high medical expenses, loss of productivity, 
diminished social function and reduced quality of life (Evans, et al., 1993). 
Approximately 44 million people demonstrate signs of elephantiasis, lymphoedema 
and genital pathology (Ottesen, et al., 1997). Persons with chronic manifestations of 
the disease are often unable to work or marry, become dependent for care and 
financial support and consequently lead to lost self-confidence. Thus, LF has been 
identified by the World Health Organization (WHO) as the second leading causes of 
permanent and long-term disability world-wide (WHO, 1997).  
 
 
These filarial infections affect individuals from all age groups and races. Men are more 
susceptible compared to woman and children (Kazura, 1999). This phenomenon may 
be explained by the greater exposure of men to mosquito vectors at work. In endemic 
areas, children are usually exposed to this infection early in their life and as many as 
one third of the children were infected before the age of five (Witt & Ottesen, 2001).  
 
The total global burden of LF is not known and mapping of its endemicity and 
prevalence is on-going. LF is the most prevalent filarial infection of humans, most of 
which is caused by W. bancrofti, while the closely related species, B. malayi and B. 
timori cause the remaining infections (Taylor, 2003). Of the three parasites causing LF, 
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W. bancrofti accounts for over 90% of the global burden (WHO, 2002a,b). It is endemic 
in India, Africa, South America, Indonesia, Burma, Vietnam, Egypt and China. B. 
malayi is limited in distribution to Asia (India, China, Indonesia, Philippines, Thailand, 
Vietnam and Malaysia) and B. timori to a few islands in Indonesia (WHO, 2003).  
 
Basically, three groups of people will be found in filarial-endemic areas (Ottesen, 1992, 
1993; Ottesen, and Campbell, 1994). There are those who are exposed to the infection 
but display no evidence of disease, these are the so-called as endemic normals; the 
second group are those who are clinically asymptomatic but demonstrate presence of 
the larvae (asymptomatic microfilaraemics). The third groups are those with chronic 
disease such as chronic lymphoedema, hydrocele and elephantiasis. Infected people 
suffer episodes of acute filarial disease such as acute filarial lymphangitis. This is 
believed to be partly due to the result of an immunological reaction to dead or dying 
adult worms which have either been killed by the immune system or by chemotherapy 
(Dreyer et al., 1999a, b). The compromised lymphatic function coupled with 
accumulation of protein-rich fluid in the tissue predisposes the limbs to bacterial 
secondary infection, and is an important risk factor for development of elephantiasis 
(Dissanayake et al., 1995) 
 
Lymphatic filariasis can be transmitted by more than 70 species and subspecies of 
mosquitoes. However, the principal mosquito species that are efficient vectors are 
found in the following four genuses:  Anopheles (W. bancrofti, B. malayi and B. timori), 
Aedes (W. bancrofti and B. malayi), Culex (W. bancrofti) and Mansonia (W. bancrofti 
and B. malayi) (Scott, 2000). Rural-urban migration and uncontrolled urbanization often 
lead to over burdening of sewerage and waste-water systems. The resulting pools of 
stagnant, polluted water provide an ideal breeding ground for Culex quinquefasciatus, 
a major vector of filariasis (Ottesen, et al., 1997; Mak, 1987). In contrast to 
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Anophelines, Culicines can efficiently transmit filariasis in situations where the 
microfilaria (mf) density is low (Webber, 1991). 
 
1.3 Wuchereria bancrofti 
W. bancrofti is a filarial nematode which lives in lymphatic channels and lymph nodes 
of humans. The adult worm is elongated and slender (30 to 100 mm long by 100 to 300 
µm wide); and males are about half the size of females. The width of the microfilaria 
(mf) is the diameter of a red blood cell and the length is 250 to 300 µm. Adults produce 
mf measuring 244 to 296 µm by 7.5 to 10 µm, which are sheathed and have nocturnal 
periodicity, except for the South Pacific strain which have the absence of marked 
periodicity (Cross, 2003). W. bancrofti belongs to the class of Secernentea, subclass of 
Spiruria, a family of Filariidae and super family of Filarioidea. 
 
Elephantiasis has been written about since the time of the early Greeks and Romans. 
The larval mf was first seen in hydrocele fluid by the French surgeon Jean-Nicolas 
Demarquay in 1863 and in urine by Otto Henry Wucherer in Brazil in 1866. The adult 
worm was described by Joseph Bancroft in 1876 and named Filarial bancrofti in his 
honor by the British helminthologist, Thomas Spencer Cobbold. The discovery of the 
life cycle by Patrick Manson in 1877 is regarded as one of the most significant 
discoveries in tropical medicine (Cross, 2003).   
 
The life cycle of W. bancrofti is shown in figure 1.2. When an infected mosquito bites a 
person who has lymphatic filariasis, the mf circulating in the person's blood enter and 
infect the mosquito. The mf passes from the mosquito through skin, and travel to lymph 
vessels. In the human lymph vessels they grow into adults and these adult worm lives 
for about 5–10 years. When matured, the adult worms mate and release millions of mf 
into their host blood system; these in turn are picked up by mosquitoes during their 
blood meal.  
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Figure 1.2 The schematic life cycle of W. bancrofti (CDC Image Library, 2004). 
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1.3.1 Pathology and Clinical Manifestation 
LF can present a wide variety of clinical manifestations, ranging from apparently 
asymptomatic cases to severe disfigurement of the limbs and genitalia. Following 
infection with third stage larvae there is usually a period of vigorous immune response 
to the invading larvae (Dreyer et al., 2000). The incubation phase from the point of 
infection to the time of appearance of first mf seems to be symptomless, but in some 
cases transient lymphatic inflammation occurred. Then the second stage, acute or 
inflammatory phase follows. This is the time when females reach maturity and releases 
the mf causing intense lymphatic inflammation, chills, fever, swollen lymph nodes, 
hydrocele and lymphadenitis to the infected human (Dreyer et al., 2000). 
 
Lymphoedema is the worst clinical manifestations of lymphatic filariasis. An important 
contributor to this condition is the repeated adenolymphangitis and cellulitis caused by 
secondary bacterial infections (Dissanayake et al., 1995). This can result in gross 
enlargement of the affected limbs and with W. bancrofti infections, these enlargements 
are usually unilateral (Figure 1.3 a, b, c, d). Besides being physically handicapped, 
patients’ abilities to carry out their daily activities are greatly restricted. There are four 
different stages of lymphoedema. In the initial stage, the lymphoedema can 
spontaneously be reversible through elevation and resulted in no skin changes. In the 
final stage, the lymphoedema is non-reversible, skin thickens and accompanied by 
warts or papilloma (WHO, 1992).   
 
The mf in the blood and lungs can also cause an IgE-mediated allergic response which 
can result in asthma-like symptoms (tropical pulmonary eosinophilia or TPE).   
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                       (a)                        (b)                        (c)                            (d) 
 
Figure 1.3 Elephantiasis of the legs due to the lymphatic filariasis, (a) Elephantiasis 
of the legs due to lymphatic filariasis; (b) Elephantiasis of the leg in a 
young mother (c) Comparison of a normal and diseased leg of a young 
woman with elephantiasis; (d) Close-up of the legs of a 64-year-old coir 
factory worker with elephantiasis. She has been infected for 45 years 
(TDR Image Library, 2005). 
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1.3.2 Diagnosis of Bancroftian Filariasis 
LF is diagnosed by a combination of the appropriate epidemiological history, physical 
findings and laboratory tests. Accurate and early diagnosis of filarial infection, followed 
by appropriate treatment can prevent sufferings due to the irreversible chronic 
elephantiasis.  Signs of chronics filariasis are easily recognized, especially among 
individuals living in the endemic areas. However detection of adenolymphangitis 
(filarial fever) or TPE among suspected patients may not be as easy. Diagnosis is not 
only important to the infected individuals but is also a useful screening tool for the 
mapping of the endemic areas which is the first important step towards realizing the 
success of the lymphatic filariasis elimination program (WHO, 1997; 2002a,b). 
 
1.3.2.1 Direct physical examination and survey 
Information for the distribution of infection and disease can be assessed by rapid 
assessment through questionnaire among local residents. In areas where 
questionnaires cannot be administered or patients are not knowledgeable about the 
disease prevalence, physical examinations can be used as a rapid assessment tool 
(WHO, 2000) to look for lymphoedema of the limbs or hydrocele in males.    
 
1.3.2.2 Thick blood film (TBF) 
The accurate diagnosis of active infection can be made essentially only by detecting mf 
in the blood of infected individuals (Weil, 1987). The simplest method is a thick blood 
film of capillary blood stained with Giemsa stain (Khamboonruang et al., 1987). For 
epidemiological screening, 60 µl of finger-prick blood can be dried on a slide, stained 
and examined under a microscope. Disadvantages of thick blood films include the 
need to collect blood at night since the mf in peripheral blood peak between 10 p.m. 
and 2 a.m. The sensitivity of this method is relatively low, leading to misdiagnoses of 
people with low-density infection, amicrofilaraemic stage of infection and single sex 
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infection.  Consequently this allows them to progress to irreversible major lymphatic 
damages (Braga et al., 2003).  
 
1.3.2.3 Concentration techniques 
Use of concentration techniques increases the sensitivity but amicrofilaraemic cases 
will still not be detected. An old but still widely used method is that Knott (1935). One 
milliliter of blood is added to 9 ml of a 2% formalin solution in water. After red cell lysis 
is complete, the mixture is centrifuged and the deposit is examined for mf. The 
theoretical detection limit is one mf per ml. The problem is when blood is processed 
from individuals with a large amount of plasma gamma globulin. The formalin 
precipitates the protein and makes the examination of the deposit difficult. The Knott’s 
method has been improved by Melrose et al. (2000) who add a small amount of Triton 
100-X to the diluents which dissolves most of the proteingenous deposit and enhances 
the visibility of the mf. Another technique is membrane filter technique in which 1-5 ml 
of blood which has been diluted in water is passed through a filter fitted with a 
polycarbonate membrane which traps the mf. The membrane is removed and the mf is 
stained and counted (Moulia-Pelat et al., 1992; McMahon et al., 1979).  
 
1.3.2.4 Ultrasonography 
High-frequency ultrasonography can directly visualize adult worms in the dilated 
lymphatics. It has being used to detect adult worms in the scrotum and breast (Amaral 
et al., 1994; Dreyer et al., 1996a,b; 1999c) and has detected viable worms in children 
(Dreyer et al., 1999a). 
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1.3.2.5 Polymerase chain reaction 
PCR methods have been successfully used for the detection of parasite-specific DNA 
of W. bancrofti in blood, plasma, paraffin-embedded tissues sections (McCarthy et al., 
1996) and sputum (Abbasi et al., 1996, 1999). PCR assays offer rapidity, higher 
sensitivity and specificity over conventional dissection and microscopic technique but 
they are relatively expensive (Zhong et al., 1996). This is mainly due to the 
involvement of costly chemicals and lengthy procedures of DNA extractions and 
facilities not often available in filarial-endemic areas. A highly sensitive and specific 
PCR assay, based on Ssp I repeats sequence, has been developed for detecting W. 
bancrofti in human blood and vectors (Zhong et al., 1996). This Ssp I PCR assay was 
found to be highly species specific, as it did not detect the DNA of a closely related 
filarial parasite, B. malayi and also proved to be highly sensitive as it did detect as little 
as 0.04 pg of W. bancrofti DNA (Hoti et al., 2001). Therefore, it has potential 
application in rapid assessment of transmission of filariasis. 
 
1.3.2.6 Detection of circulating antigen  
Two different groups of inventors independently produced monoclonal antibodies, 
Og4C3 and AD12, which recognized a protein moiety of a major phosphocholine-
containing circulating antigen of W. bancrofti (More and Copeman, 1990; Weil, 1987).  
These antigen detection assays were found to be more convenient than the 
microfilarial detection technique since night blood sampling could be avoided as 
circulating antigens were present even in daytime blood samples (Pani et al., 2000) 
collected on filter paper (Itoh et al., 1998). 
 
The murine monoclonal antibody, Og4C3 directed against antigen of Onchocerca 
gibsoni was used successfully as the detection-antibody in a sandwich ELISA for the 
detection of circulating antigen of W. bancrofti.  However, this assay was not effective 
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in detecting antigens of B. malayi, B. timori, O. volvulus or Loa loa (More and 
Copeman, 1990).   
 
Another commercially available antigen detection assay used the AD12 monoclonal 
antibody in a rapid-format card test for the detection of bancroftian filariasis. The test is 
a rapid ICT technique using specific monoclonal and polyclonal antibodies which 
recognized the filarial antigen in the blood of infected humans. This kit (ICT Filariasis) 
that was initially manufactured by ICT Diagnostics, Balgowlah, New South Wales, 
Australia is currently marketed by Binax NowRICT, Portland, USA. It utilizes capillary or 
venous blood collected either the night or day and is very easy to handle, very fast to 
perform, can be used in the field by people with a minimum amount of training (Weil et 
al., 1997). It has previously been shown to be highly sensitive for infections with W. 
bancrofti and highly specific with respect to other filarial parasites including O. volvulus, 
B. malayi, L. loa and Mansonella Streptocerca (Weil et al., 1997). Its reported 
sensitivity and specificity rates were 96-100% and 100% respectively. Thus, this test is 
useful for mapping of endemic areas in control programs for bancroftian filariasis. 
 
1.3.2.7 Detection of anti filarial IgG4 antibody  
New and more sensitive and specific assays for diagnosis of LF have been developed 
(Dissanayake et al., 1994; Chandrashekar et al., 1994). One study on bancroftian 
filariasis reported that IgG4 antibodies reacted well with recombinant W. bancrofti SXP-
1 antigen (Engelbrecht et al., 2003). A sensitivity of 100% was obtained in patients with 
patent W. bancrofti infections using the Wb-SXP-1 antigen in IgG4-ELISA (Rao et al., 
2000). This recombinant antigen has now being developed into a rapid test for the 
identification of total IgG antibodies to Wb-SXP-1. The test is a flow-through 
immunofiltration test that employed colloidal gold-protein A as the antibody capture 
reagent (Baskar et al., 2004). Another two recombinant-antigens, namely Bm14 and 
BmR1, have been developed into IgG4 antibody detection tests and have been shown 
  
 
13 
to be sensitive and specific for determining LF infection/exposure. The Bm14 antigen 
was reported to be equally sensitive for Wuchereria and Brugia infection/exposure 
(Ramzy et al., 1995; Weil et al., 1999). This antigen has some cross-reactivity with sera 
from patients with other filarial infections (loiasis and onchocerciasis), but not with sera 
from people with non-filarial nematode infections (Ramzy et al, 1995). Field studies in 
Egypt showed that prevalence rates of antibody to Bm14 prior to initiation of MDA were 
much higher than antigen or mf prevalence rates in young children (Weil et al, 1999). 
The BmR1 antigen which performed well in the detection of brugia infections, has 
limited sensitivity in detecting W. bancrofti infection (Lammie et al, 2004). 
  
1.3.3 Treatment and prognosis 
Individuals found to be mf-positive or filarial antigen-positive during the initial 
assessment period, monitoring, or on voluntary examination should be treated with 
diethylcarbamazine (DEC). DEC has been used to treat filariasis since 1947 (Santiago-
Stevenson et al., 1947) and still is the most widely used anti-filarial. Many countries 
use a 12-day course (W. bancrofti) or a 6-day course (B. malayi) of 6 mg/kg/day of 
DEC (WHO, 1992a,b). In some of the control programs in the Pacific and Papua New 
Guinea, colour-coded DEC tablets are used without weighing the patient. A 300mg 
tablet is given to adults and a 150mg tablet to children. DEC is very effective in killing 
microfilaria but only partly effective against adult filarial parasites. This is evidenced by 
the work by Weil et al. (1988) who demonstrated that filarial antigenaemia persists for 
up to 12 months after DEC therapy. Figueredo-Silva et al. (1996) removed nodules 
after DEC treatment and found that all contained degenerating adult worms, thus 
proving that DEC has a limited amount of macrofilaricidal activity. 
 
A study showed that single dose albendazole (400mg) has similar efficacy in the 
clearance of mf as that of DEC (6 mg/kg) or the co-administration of the two drugs, i.e. 
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albendazole (400mg) plus DEC (6 mg/kg) (Pani et al., 2002). This showed that 
albendazole can be used in mass single dose administration for the control of LF.  
 
In areas co-endemic with onchocerciasis or loiasis, ivermectin has been used widely 
as microfilaricidal in LF cases to avoid the potentially severe allergic reaction with 
DEC. Ivermectin is a highly effective and generally well-tolerated drug for the treatment 
of LF (Brown et al., 2000) and a series of single dose ranging studies from 20 to 
200µg/kg for the treatment of bancroftian filariasis was effective in decreasing blood 
microfilaria density (Cartel et al., 1990a,b,c,d; Kumaraswami et al., 1988). Ivermectin 
with higher doses resulting in more sustained clearance of mf (Kar et al., 1993a, b; 
Kumaraswami et al., 1988). It is a very effective microfilaricide but how effective it is 
against adult worm is a contentious issue.  
 
Simple hygiene measures, supplemented with antibiotics or antibacterial cream helps 
prevent damage tissues from worsening, stop secondary bacterial infections and help 
to reduce the limb enlargement caused by repeated filarial and bacterial infections 
(Ottesen, 1997). Effective hygiene measures include regular twice-daily washing of the 
affected parts with soap and water; raising the affected limb at night; keeping the nails 
clean; wearing shoes; and using local antiseptics or antibiotic creams to treat small 
wounds. 
 
Anti filarial drugs alone will not be able to revert the fibrotic changes of the skin and 
connective tissue involved (Kazura, 1999). Now expertise is available for surgical 
therapy of genital manifestations of filariasis. Generally, the surgery involves removal 
of the excess fibrotic tissue. The most common surgery for hydrocele is complete 
excision of the sac. However, its effect is short lasting as the edema will recur. As an 
alternative, micro vascular surgery can be performed (Kazura, 1999) which involves 
anastomosis of the lymph vessels with the nearby veins (WHO, 2002a,b).   
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1.3.4 Global Programme to Eliminate Lymphatic Filariasis (GPELF) 
The goal of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) is 
defined as “The Elimination of Lymphatic Filariasis as a Public Health Problem by 
2020” (WHO, 1997). The 50th World Health Assembly in 1997 had passed a resolution 
identifying the elimination of LF as a public health problem, a priority. This includes 
some strategic plans which are identified to have four major elements (WHO, 1999a,b) 
namely the interruption of transmission; the prevention of disability; the provision of 
additional technical support; and the implementation of operational research (up-
scaling program). Interruption in transmission can be achieved in reducing and 
eliminating the reservoir of mf through treating the human population and by reducing 
contact between humans and mosquito vectors (Chaubal et al., 2003).  
 
The traditional method i.e. thick blood smear examination which was used before, have 
a sensitivity of only 25-40% (WHO, 1998). If it is the sole diagnostic method used in 
post intervention surveillance, many false negatives will occur; hence a low incidence 
will not actually indicate successful interruption of transmission. Therefore, there is a 
clear need for specific, sensitive and field applicable tests as to ensure the success of 
this global elimination program. 
 
Mass drug administration (MDA) of at-risk population (Freeman et al., 2001) is being 
used to interrupt transmission. This is based on the evidence of the effectiveness of a 
single dose of DEC (6mg/kg) in the clearance of mf and sustaining this over a period of 
at least one year (Farid et al., 2003). Thus this reduces the number of mf in the blood 
to levels below which the mosquito vectors can no longer transmit infection. These 
comprise two approaches. First is the once-yearly treatment with single dose of two 
drugs given together i.e. albendazole plus either ivermectin or DEC for 4-6 years 
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(Molyneux, 2003). The second approach is the use of DEC-fortified table or cooking 
salt for 1-2 years (Lymphatic Filariasis Support Center, 2004). 
 
GlaxoSmithKline has committed to provide the entire supply of albendazole, while 
Merck & Co. Inc., committed to supply ivermectin in those African countries with 
onchocerciasis and loaisis (WHO, 1997). By the end of 2001, nearly 26 million people 
in over 22 countries had been administered the combination drugs in MDA campaigns 
(WHO, 2002a,b). Vector control has been used as an important adjunct in the LF 
program in certain areas. The strategy to prevent disability is designed to encourage 
home-based self-care, i.e. regular skin care, exercise and appropriate footwear, and by 
trying to develop facilities in the health care system for disability control (WHO, 1997). 
The control of lymphoedema management is the prevention of acute ADL attacks 
through basic hygiene by using soap and water, and prevention and treatment of small 
skin lesions with application of topical antifungal or antibiotic cream (WHO, 2000). This 
basic hygiene can stop the acute attacks and improve the patient’s condition.  
 
 
1.3.5 Lymphatic Filariasis in the Malaysian Context 
The Filariasis Control Program in Malaysia was established more than 30 years ago; 
however the disease is still a public health problem in rural areas, especially in some 
areas in Sarawak, Pahang, Terengganu, Johor, Perak, Sabah, Kedah and Kelantan. 
More than 85% of the annual incidence rate of lymphatic filariasis in Malaysia is due to 
B. malayi (Ministry of Health, 1990-1999). The annual incidence of chronic 
elephantiasis is around 5 to 10, and about 2.9 million people are at risk of acquiring 
this disfiguring disease (Che Abdullah, 2004). In early 1960, the Vector Borne Disease 
Control Unit (RKPBV) of Ministry of Health initiated filariasis surveillance to detect and 
treat every filariasis cases. Later, three approaches were implemented in Malaysia, 
namely, mass treatment and treatment of index cases; eradication and control of the 
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vectors; and avoiding human-mosquito contact (Noorhayati, 1999). In June 2003, 
Malaysia started the National Program for Elimination of Lymphatic Filariasis and the 
aim is to eliminate lymphatic filariasis  as a public health problem by 2013 (Che 
Abdullah, 2004).  
 
The mosquito vectors belonging to the Anopheles and Mansonia genera are involved 
in the transmission of filariasis in Malaysia, the latter being the more important vector. 
Anopheles donaldi was found to be infected with infective larvae of B. malayi 
(Vythilingam et al., 1996) where the peak biting time was around 11 pm to 12 am. 
Monkeys and domestic cats are the reservoir hosts for the subperiodic strain of B. 
malayi (Marzhuki et al., 1993). The most common monkeys in Malaysia are the 
macaques (Macaca spp.) and leaf monkeys (Presbytis spp.) [WHO, 1984].  
 
The historical record of filariasis in Malaysia can be categorized under three phases 
(Lim, 2005). The first phase (1908-1952) mainly focused on the statistics of microfilarial 
carriers which had been identified in Hospital Kuala Lumpur and Raub. The second 
phase (1953-1961) dealt with the mapping of endemic foci in East Pahang, 
Terengganu and Kelantan. At this phase it was found that Culex quinquefasciatus was 
implicated for spreading bancroftian filariasis. Successful mass chemotherapheutic 
trials were conducted in two villages of Pahang i.e. treatment regime of weekly and 
monthly doses of diethylcarbamazine (DEC) at 4-6 mg/kg body weight for 6 weeks and 
6 months respectively. The activities of the third phase (1962-onwards) was mainly 
towards identifying the most suitable method for filariasis control.  
 
In Malaysia mf densities in many infected individuals are too low to be detected by the 
traditional method of thick blood smear examination. In addition, thick blood smears do 
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not allow for the detection of individuals harbouring nonfertile worms, pre-patent 
infections and single sex infections (Turner et al., 1992).  
 
 In the official report of the district of Pasir Mas in the state of Kelantan, one case in 
2428 samples (0.04%) from the subdistrict of Gual Periok was detected in 1997; and in 
2000, two cases were detected in 803 samples (0.25%) from the subdistricts of Gual 
Periok and Rantau Panjang (Pasir Mas Health Office 1997–2001). However, no cases 
were reported in 1998 (1385 samples), 1999 (985 samples) and 2001 (1100 samples). 
These figures probably do not reflect the true prevalence of the infection as it is based 
on the insensitive thick blood smear examination. Recently, Rahmah et al (2003a) 
conducted a filariasis survey on 5138 pupils schools located in the subdistricts (mukim) 
of Pasir Mas bordering Thailand border. Out of 2439 boys and 2699 girls screened. 
Brugia malayi infection was detected in 18 children, giving an overall prevalence of 
0.35% (18 of 5138). The investigators employed a recombinant antigen (BmR1) based 
ELISA (Brugia-Elisa) that has been shown to highly specific and sensitive for detection 
of brugian filariasis (Supali et al., 2004; Rahmah et al., 2003b). In 2001, Lim et al had 
collected a total of 1,134 finger-pricked blood samples from residents of Setiu, 
Terengganu and the findings showed that 0.26% (3/1,134) were positive by thick blood 
smear examination, while 2.47% (28/1,134) were positive using Brugia-Elisa.  In 
another study conducted by Jamail et al (2005) among residents of seven endemic 
districts in the state of Sarawak, the overall prevalence of brugian filariasis as 
determined by a rapid test was 9.4% while that determined by microscopy was 0.90% 
thus the dipstick detected about 10 times more cases than microscopy.  The test 
employed was BRUGIArapid™ dipstick test, which is also based on the BmR1 
recombinant antigen.  Equal percentages of adults and children were found to be 
positive by the dipstick whereas microscopy showed that the number of infected 
children was seven times less than infected adults. Thus the results of the above 
studies showed that the use of insensitive microscopic examination leads to many 
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untreated cases of infected people, which will become reservoir for the transmission of 
the infection. Due to its superior sensitivity, BRUGIArapid™ is being employed by the 
Ministry of Health Malaysia to assist in the National Lymphatic Filariasis Elimination 
Program. 
 
 
 
1.4 Onchocerciasis 
Onchocerciasis or river blindness is a major public-health and socio-economic problem 
in many rural areas (Shah et al., 1987). It is caused by the filarial worm Onchocerca 
volvulus, vectored by the black fly, Simulium spp. (Cox, 2002; Greene, 1992) including 
S. damnosum (Shah et al., 1987). It infects about 20 million people and is endemic in 
28 countries in Africa, 6 countries in the Americas and in Yemen (WHO, 2002a,b). 
Onchocerciasis is one of the leading causes of infectious blindness worldwide (Klotz et 
al., 2000; Duke, 1990). It has caused visual impairment in 500,000 and blindness in 
270,000 people, rendering onchocerciasis the second most frequent cause of 
preventable blindness in sub-Saharan Africa (WHO, 1995). Rarely life-threatening, the 
disease cause chronic suffering and severe disability (Figure 1.5).  
 
The most important signs are blindness and chronic skin disease such as scaly, itchy 
and unusual nodular skin (Cox, 2002; Pogonka et al., 1997). Onchocerciasis used to 
be the major cause of blindness throughout sub-Saharan Africa, often affecting more 
than 50% of the inhabitants of towns and villages in endemic areas (Greene, 1992). In 
some small communities in Africa and Central America, most of the people of middle 
age and over are blind.  
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                  (a)                                        (b)                                         (c) 
 
Figure 1.4 Two signs of onchocerciasis; (a) and (b) a 60-year-old male farmer 
scratching his legs which show the tell-tale depigmentation (leopard 
skin), the consequence of years of fenzied scratching. Having the 
incessant itching chronic skin disease, and (c) close up picture of an 
eye damaged (river blindness) as a result of infection with O. volvulus 
(TDR Image Library, 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
21 
1.4.1 Onchocerca volvulus 
Infection with O. volvulus is initiated by the feeding of an infected black fly on a human. 
There are no reservoir hosts for this parasite, but some experimental infections have 
been established in non-human models such as cattle (Yien-Ming and Bianco, 1995), 
chimpanzees and mice (Abraham et al., 2001). It is a member of class of Secernentea, 
subclass of Spiruria, order Spirurida, belonged to the superfamily of Filarioidea and a 
family member of Onchocercidae. 
 
The morphology is similar to that of W. bancrofti. They are slender and blunt at both 
ends. Lips and a buccal capsule are absent, and 2 circles of four papillae each 
surround the mouth. Males are 19 to 42 cm long by 130 to 210 µm wide and the 
females are 33.5 to 50 cm long by 270 to 400 µm wide, while the mf are 300mm in 
length and 0.8mm in diameter, unsheathed with sharply pointed, curved tails. 
 
1.4.2 Life cycle of Onchocerca volvulus 
Human onchocerciasis is caused by the filarial parasite O. volvulus whose life cycle 
occurs in two different hosts namely Simulium black flies and humans (Figure 1.6). 
Simulium vectors breed in fast flowing rivers. A female worm may produce 1000 mf per 
day which is shed in the tissues and blood of their human host (Klotz et al., 2000). The 
life cycle begins when a parasitized female black fly takes a blood-meal. The host’s 
skin is stretched by the fly’s apical teeth and sliced by its mandibles. The larvae from 
the fly then move to the subcutaneous tissues (molt to L3, the infective stage for 
human) where they migrate, form and lodge in nodules, and slowly mature into adult 
worms (L4) in the subcutaneous tissue for years (Klotz et al., 2000). The adult worm 
locates to a single niche in the subcutaneous tissue. New worms form new nodules or 
find existing nodules and cluster together. After mating, eggs from inside the female 
worm develop into mf and leave the worm one by one. The mf migrate throughout this 
tissue, inducing injury to a variety of anatomical sites contiguous with that tissue or 
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where they die after several years (Klotz et al., 2000). When female black flies take a 
blood meal they ingest the mf that will then undergo transitions to L2 stage in the fly. 
 
1.4.3 Pathology and clinical disease 
Unlike other filarial infections, the problems of onchocerciasis are caused by mf rather 
than adult worms. An early sign of infection with Onchocerca is the raised nodules that 
can be seen under the skin. These are most often seen in areas over a bony 
prominence and may develop into a firm, non-tender nodule called as onchocercomata 
which contained adult worms (Klotz et al., 2000). It has been suggested that this 
phenomenon occurs because the larvae are immobilized in these locations long 
enough for them to be trapped by the body’s cellular defense mechanisms. This 
migration lead to intense pruritus manifesting as dermatitis, whereby the skin may 
become thickened, edematous, wrinkled and depigmented (Klotz et al., 2000).  
 
The mf can be found free in the fluid within the nodules and in the dermal layers of the 
skin, spreading away from the nodules containing the adults. Mf also can be found in 
the blood and eye during heavy infection (Klotz et al., 2000). Mf can be killed only 
during a limited period of their development, after which the larvae become resistant to 
attack by the immune response (Abraham et al., 2001). Reactions to dead mf around 
these nodules can lead to several unpleasant conditions, including serious visual 
impairment and blindness, skin rashes, lesions, itching and depigmentation of the skin, 
lymphadenitis (lead to hanging groin) and general debilitation (Klotz et al., 2000). In the 
skin, there is destruction of the elastic tissues and the formation of redundant folds.  
 
Dead mf in the eye leads to an inflammatory immune response and the eventual 
formation of secondary cataracts and ocular lesions. Because of this, heavy infections 
often lead to progressive blindness. Much of the pathology associated with 
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onchocerciasis takes place during the immune responses against the mf that are found 
in the skin and ocular tissues (Kazura et al., 1993).   
 
The establishment of a chronic filarial infection in humans is accompanied by 
characteristic cell-mediated and humoral immune responses. The antifilarial humoral 
immune response is characterized by high levels of immunoglobulin E (IgE) 
(Kurniawan et al., 1993), eosinophilia (Gbakima et al., 1996). In areas of endemicity, 
most filarial infections are initiated during early childhood (Gbakima, 1996). The 
precise pathogenesis of onchocerciasis lesions is still unknown. 
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Figure 1.5 The incubation phase of filarial parasite which affective from the point of 
infection to the time of appearance of first mf and resulted in eye 
lesions, altered pigmentation and loss of elasticity of skin (Cross, 1992). 
 
 
 
 
 
 
 
 
